Oncology and Hematology - Global Oncology Academy

65-80 of 790

Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
MinuteCE®
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Ticiana Leal, MD
0.50 program credits
- Ticiana Leal, MD
0.50 program credits
MinuteCE®
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
Neal Ready, MD, PhD; Ticiana Leal, MD
0.50 credits 4 episodes
- Neal Ready, MD, PhD
- Ticiana Leal, MD
0.50 credits 4 episodes
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
September 24, 2026
1.00 credit
From Data to Decision: Patient Selection and Real-World Application
From Data to Decision: Patient Selection and Real-World Application
MinuteCE®
From Data to Decision: Patient Selection and Real-World Application
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
MinuteCE®
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
The Evidence Base: Key Trials and Emerging Data
The Evidence Base: Key Trials and Emerging Data
MinuteCE®
The Evidence Base: Key Trials and Emerging Data
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
MinuteCE®
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 credits 4 episodes
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 credits 4 episodes
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Project Oncology®
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP; Jason Starr, DO
- Charles Turck, PharmD, BCPS, BCCCP
- Jason Starr, DO
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
MinuteCE®
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 program credits
The Power of Timing: Therapies That Change Outcomes
The Power of Timing: Therapies That Change Outcomes
MinuteCE®
The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Precision in Practice—Bringing Targeted Therapy to mHSPC
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Project Oncology®
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Alexandria May, PharmD, BCPS; Prithviraj Bose, MD
- Alexandria May, PharmD, BCPS
- Prithviraj Bose, MD
In-Person & Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul

5/10